Cargando…
527. Lower Risk of ICU Admission with Remdesivir in Patients Hospitalized with COVID-19 Pneumonia
BACKGROUND: Remdesivir (RDV) was approved by FDA in October 2020 for use in hospitalized patients with COVID-19. We examined the association between RDV treatment and ICU admission in patients hospitalized with COVID-19 pneumonia requiring supplemental oxygen (but not advanced respiratory support) i...
Autores principales: | Lim, Sarah, Schreiner, Pamela, Lifson, Alan, Bye, Erica, Como-Sabetti, Kathryn, Lynfield, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644404/ http://dx.doi.org/10.1093/ofid/ofab466.726 |
Ejemplares similares
-
715. Increase in Reported Respiratory Syncytial Virus Cases Among Adults in the Minneapolis-St. Paul Metropolitan Area, 2014–2018
por: Como-Sabetti, Kathryn, et al.
Publicado: (2018) -
186. Characteristics of COVID-19 Vaccine Breakthrough Cases in Minnesota, 2021
por: Meyer, Stephanie, et al.
Publicado: (2021) -
982. Summer Outbreak of Severe RSV-B Disease, Minnesota, 2017
por: Thielen, Beth, et al.
Publicado: (2018) -
1925. Prevalence of SARS-CoV-2 Infection in Immunocompromised Patients Following Receipt of Tixagevimab/Cilgavimab
por: Lim, Sarah, et al.
Publicado: (2022) -
685. Correlation Between Hospitalized Influenza and Group A Streptococcus Infections in Minnesota, 2010–2016
por: Arogbokun, Olufunmilayo, et al.
Publicado: (2018)